Shots:
PharmaShots’ May Edition explores how AI is transforming commercial strategies across the healthcare ecosystem by enabling predictive analytics, personalized engagement, dynamic launch planning, and real-time omnichannel optimization while balancing compliance and measurable ROI.
The magazine highlights key industry movements shaping global biopharma, including AI-driven drug discovery collaborations, strategic M&A activity, advancements in cell and…
Shots:
Approval activity continued strongly into April 2026, with the US FDA authorizing two significant therapies across metabolic disease and infectious disease, reinforcing the agency’s focus on chronic disease management, long-term treatment innovation, and broader patient access.
Two notable therapies achieved regulatory clearance: Eli Lilly’s Foundayo for weight loss in obese or overweight adults with weight-related conditions,…
Shots:
The company has filed a P-I/II IND with the FDA to begin clinical trials of CYPS317 for mod. to sev. Psoriasis
In animal studies, a single dose of CYPS317 matched or exceeded multiple anti-IL-23 mAb doses, showing durable effects and reduced disease recurrence
CYPS317 is an investigational allogeneic fibroblast spheroid therapy for mod. to…
Chronic diseases like diabetes, heart disease, and hypertension are among the leading causes of death worldwide. These conditions affect millions of people, placing a significant strain on individuals, families, and healthcare systems. While pharmaceutical advancements have revolutionized treatment options, they cannot address every aspect of a patient’s journey.
To tackle the complex challenges of chronic disease…

